Risk Factors Update Summary
- Transition of commercialization responsibilities for Crysvita in the U.S. and Canada back to KKC.
- Decrease in available cash, cash equivalents, and marketable debt securities from $896 million to $777 million.
- Construction of gene therapy manufacturing facility in Bedford, Massachusetts expected to complete in 2023.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1515673&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.